Evidence map›Paper›PMID 39789068›Full record

ArticleScientific reports2025

Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients.

Gyöngyvér Orsolya Sándor, Gyöngyi Farkas, Gábor Székely, Péter Ágoston, Kliton Jorgo, László Gesztesi, Tibor Major, Csilla Pesznyák, András Herein, Gábor Stelczer and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gyöngyvér Orsolya SándorDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, 1122, Ráth György utca 7-9, Budapest, Hungary.
Gyöngyi FarkasDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, 1122, Ráth György utca 7-9, Budapest, Hungary.
Gábor SzékelyDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, 1122, Ráth György utca 7-9, Budapest, Hungary.
Péter ÁgostonCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Kliton JorgoCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
László GesztesiCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Tibor MajorNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary.
Csilla PesznyákCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
András HereinNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary.
Gábor StelczerCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Dalma MihályCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Georgina FröhlichCentre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Zsolt JurányiDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, 1122, Ráth György utca 7-9, Budapest, Hungary. juranyi.zsolt@semmelweis-univ.hu.
Zoltán Takácsi-NagyNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary.
Csaba PolgárNational Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary.
Zsuzsa S KocsisDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, 1122, Ráth György utca 7-9, Budapest, Hungary.

Funding

National Research, Development and Innovation Fund 2020-1.1.6-JÖVŐ-2021-00008National Research, Development and Innovation Fund 2022-2.1.1-NL-2022-00010
6 · The paper itself

Abstract

Due to the better survival of patients with tumorous diseases, it is increasingly important to predict the side effects of radiotherapy, for which the Radiation-Induced Lymphocyte Apoptosis (RILA) method is proving to be effective in multicentric studies. Prostate cancer is the leading cause of cancer-related deaths among men worldwide, which is usually treated with radiotherapy. We recruited 49 patients with localized prostate cancer and performed RILA measurements before radiotherapy. Patients were treated with CyberKnife (35-40 Gy) or high-dose-rate brachytherapy (1 × 21 Gy). We performed chromosome aberration test for five years and graded side effects, IPSS and QoL questionnaire scores were recorded. We found that RILA% correlated with the IPSS increase (p = 0.0016, r=-0.44), which was confirmed with negative binomial regression (p = 0.0013). The negative predictive value for severe urinary side effects according to the IPSS questionnaire was 87.9% at the lower tertile of RILA values. Chromosome aberrations also correlated with side effects, but when we built models including variables of baseline and treatment characteristics of the patients, RILA, and chromosome aberrations, only RILA predicted a late increase in IPSS score (p < 0.0001, adjusted R

Indexed as

ApoptosisLymphocytesProstatic NeoplasmsAgedAged, 80 and overBrachytherapyChromosome AberrationsHumansMaleMiddle AgedRadiosurgery

Identifiers

PMID39789068
PMCPMC11718057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.